Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas

BACKGROUND: Dopamine agonists (DAs) are the first-line treatment for prolactinomas, which account for 25–30% of functioning pituitary adenomas, and bromocriptine (BRC) is the only commercially available DAs in China. However, tumors are resistant to therapy in 5–18% of patients. METHODS: The exomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Hua, Wang, Fei, Lan, Xiaolei, Li, Chuzhong, Feng, Jie, Bai, Jiwei, Cao, Lei, Gui, Songbai, Hong, Lichuan, Zhang, Yazhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407330/
https://www.ncbi.nlm.nih.gov/pubmed/25884948
http://dx.doi.org/10.1186/s12885-015-1267-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407330/
https://www.ncbi.nlm.nih.gov/pubmed/25884948
http://dx.doi.org/10.1186/s12885-015-1267-0

Ejemplares similares